Eton Pharmaceuticals, Inc. (ETON) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | (m) | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 19.08M USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 115.81M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | (m) | $19.08M | (m) | (m) | $115.81M | (m) |
| 2026-03-31 | (m) | (m) | (m) | $18.94M | (m) | (m) | $97.71M | (m) |
| 2025-12-31 | (m) | (m) | $8.79M | $21.77M | (m) | (m) | $92.11M | (m) |
| 2025-09-30 | (m) | (m) | (m) | $27.59M | (m) | (m) | $104.51M | (m) |
| 2025-06-30 | (m) | (m) | (m) | $27.41M | (m) | (m) | $101.68M | (m) |
| 2024-12-31 | (m) | (m) | $0.00 | (m) | (m) | (m) | $76.12M | (m) |
| 2024-09-30 | (m) | (m) | $4.13M | (m) | (m) | (m) | $35.84M | (m) |
| 2024-06-30 | (m) | (m) | $4.66M | (m) | (m) | (m) | $31.82M | (m) |
| 2024-03-31 | (m) | (m) | $5.02M | (m) | (m) | (m) | $30.79M | (m) |
| 2023-12-31 | (m) | (m) | $5.38M | (m) | (m) | (m) | $31.74M | (m) |
| 2023-09-30 | (m) | (m) | $1.54M | (m) | (m) | (m) | $31.53M | (m) |
| 2023-06-30 | (m) | (m) | $1.54M | (m) | (m) | (m) | $30.93M | (m) |
| 2023-03-31 | (m) | (m) | $1.34M | (m) | (m) | (m) | $23.93M | (m) |
| 2022-12-31 | (m) | (m) | $1.03M | (m) | (m) | (m) | $25.03M | (m) |
| 2022-09-30 | (m) | (m) | $708.00K | (m) | (m) | (m) | $21.52M | (m) |
| 2022-06-30 | (m) | (m) | $364.00K | (m) | (m) | (m) | $23.05M | (m) |
| 2021-12-31 | (m) | (m) | $1.42M | (m) | (m) | (m) | $27.46M | (m) |
| 2021-09-30 | (m) | (m) | $1.09M | (m) | (m) | (m) | $26.61M | (m) |
| 2021-06-30 | (m) | (m) | $749.00K | (m) | (m) | (m) | $29.91M | (m) |
| 2021-03-31 | (m) | (m) | $385.00K | (m) | (m) | (m) | $31.19M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |